Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

被引：2
|
作者：
Takezako, Naoki [1 ]
Tokuhira, Michihide [2 ]
Sekiguchi, Naohiro [1 ]
Kizaki, Masahiro [2 ]
机构：
[1] Disaster Med Ctr, Tachikawa, Tokyo, Japan
[2] Saitama Med Ctr, Saitama, Japan
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-255
引用
收藏
页码：E142 / E143
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
    Zhang, Shilong
    Li, Jing
    Liu, Peng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
  • [32] VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients
    O'Sullivan, J. M.
    Kumar, S.
    Yeomans, C.
    Milner, G.
    Schey, S.
    Kazmi, M.
    Streetly, M. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 64 - 65
  • [33] Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    Berenson, JR
    Jagannath, S
    Barlogie, B
    Siegel, DT
    Alexanian, R
    Richardson, PG
    Irwin, D
    Alsina, M
    Rajkumar, SV
    Srkalovic, G
    Singhal, S
    Limentani, S
    Niesvizky, R
    Esseltine, DL
    Trehu, E
    Schenkein, DP
    Anderson, K
    CANCER, 2005, 104 (10) : 2141 - 2148
  • [34] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
    J R Berenson
    J D Hilger
    O Yellin
    R Dichmann
    D Patel-Donnelly
    R V Boccia
    A Bessudo
    L Stampleman
    D Gravenor
    S Eshaghian
    Y Nassir
    R A Swift
    R A Vescio
    Leukemia, 2014, 28 : 1529 - 1536
  • [35] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
    Berenson, J. R.
    Hilger, J. D.
    Yellin, O.
    Dichmann, R.
    Patel-Donnelly, D.
    Boccia, R. V.
    Bessudo, A.
    Stampleman, L.
    Gravenor, D.
    Eshaghian, S.
    Nassir, Y.
    Swift, R. A.
    Vescio, R. A.
    LEUKEMIA, 2014, 28 (07) : 1529 - 1536
  • [36] Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation**
    Vu, Minh Phuong
    Kieu, Thi Van Oanh
    Vu, Hoang
    LEUKEMIA RESEARCH REPORTS, 2023, 19
  • [37] Bortezomib-Dexamethasone or Vincristine-Doxorubicin-Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients
    Chen, R. A.
    Tu, Y.
    Cao, Y.
    Liu, L.
    Liang, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (05) : 1975 - 1984
  • [38] USE OF MAINTENANCE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE (VD) IN ADVANCED MULTIPLE MYELOMA
    Benevolo, G.
    Larocca, A.
    Pregno, P.
    Gay, F.
    Botto, B.
    Gentile, C.
    Frairia, C.
    Evangelista, A.
    Morabito, F.
    Palumbo, A.
    Vitolo, U.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 160 - 160
  • [39] Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis.
    Chanan-Khan, AA
    Richardson, P
    Lonial, S
    Siegel, D
    Jagannath, S
    Mehta, J
    Doran, J
    Singhal, S
    BLOOD, 2005, 106 (11) : 716A - 717A
  • [40] Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma
    Holmberg, Leona A.
    Green, Damian
    Libby, Edward
    Becker, P. S.
    ACTA HAEMATOLOGICA, 2020, 143 (02) : 146 - 154
12345